semaglutide fda approval date weight loss Weight-loss drug called Wegovy receives Semaglutide GLP-1 for Medical Weight

In August 2024, the TGA issued a notice advising that compounding pharmacies could not prepare medicines that are bioequivalent to, or that substitute for, currently marketed therapeutic goods, specifically targeting compounded semaglutide products that were being marketed as alternatives to Ozempic and Wegovy during the supply shortage period

During the consultation, the physician will evaluate the patient's medical history, discuss treatment options, and create a personalized plan

Movement Disorder Emergencies

K.CleallS.ReaneyM.et al (2014a)

However, Semaglutide has been licensed in the US as a weight-loss treatment under a different name, Wegovy

Patients receiving warfarin should undergo more frequent monitoring when initiating or adjusting semaglutide therapy, with warfarin dose adjustments made as necessary to maintain therapeutic anticoagulation